Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA elaborates on Visicol seizures

Executive Summary

FDA publishes "1Science Backgrounder" on Visicol-induced seizures on agency website following meeting with InKine execs. Company expressed concern that an FDA letter published in the June 27 New England Journal of Medicine "misstated or omitted" several facts about four seizures reported with use of Visicol, which is indicated for bowel cleansing before colonoscopy. In the website backgrounder, FDA clarifies per InKine's request that more than 210,000 patients have received Visicol (sodium phosphate) and no seizures had been reported since August 2001, although agency notes "there is generally under-reporting of adverse events." Backgrounder also notes that OTC sodium phosphate-containing products have been associated with three seizure reports in the published literature, although they have not been reported to FDA. InKine published a response to the NEJM letter in the online version of the June 27 publication; the response will also appear in the printed July 25 issue...

You may also be interested in...

QUOTED. 9 March 2021. Matthew Trerotola.

Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.

US FDA Addresses PFAS In Cosmetics, Aiming To Close Data Gaps

Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts